Scil Technology licensed its dental and cartilage programs. These programs were at various phases when transferred to its partners.
The program in the field of dental implantology and periodontal diseases was out-licensed to Medtronic Inc.
Scil Technology developed a novel regenerative bone substitute material for dental implantology and for surgical treatment of periodontal disease. Both product candidates were developed up to phase III before they were out-licensed to Medtronic.
Cartilage Regeneration Program
The program that was out-licensed to Sanofi is based on rhCD-RAP – recombinant human cartilage-derived retinoic acid sensitive protein. CD-RAP is a specific differentiation and maintenance factor for the regeneration of cartilage tissue.
For all projects efficacy has been successfully demonstrated in large animal studies. In these studies, signs for pain reduction have also been observed.